Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
42 hedge funds and large institutions have $20.2M invested in Cidara Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 9 closing their positions.
18% more capital invested
Capital invested by funds: $17.1M → $20.2M (+$3.09M)
0% more funds holding
Funds holding: 42 → 42 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
1.42% less ownership
Funds ownership: 38.63% → 37.21% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$362K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$180K |
| 3 |
CC
Callan Capital
La Jolla,
California
|
+$61.7K |
| 4 |
Jane Street
New York
|
+$37.3K |
| 5 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
+$32.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
-$431K |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$232K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$114K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$88K |
| 5 |
Renaissance Technologies
New York
|
-$64.4K |
CDTX Hedge Fund Activity: Q4 2022 in Review
42 of the 6,240 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2022, worth a combined $20.2M — up 18% from $17.1M a quarter earlier.
Fund positioning in CDTX was balanced in Q4 2022: 9 funds opened new positions, 9 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $362K. The largest seller was David M. Knott Jr, exiting entirely with an estimated $431K sold.
- 42 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $20.2M of Cidara Therapeutics stock for Q4 2022, up 18% quarter-over-quarter.
- 9 funds opened new Cidara Therapeutics positions in Q4 2022 and 9 closed out, a net change of 0 holders.
- The largest Cidara Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $362K added.
- The largest Cidara Therapeutics seller in Q4 2022 was David M. Knott Jr, an estimated $431K sold.
Based on aggregated 13F filings for Q4 2022.